LncRNA TP73-AS1 Exacerbates the Non-Small-Cell Lung Cancer (NSCLC) Process Via Regulating MiR-125a-3p-Mediated ACTN4

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2022 Sep 19

PMID 36118078

Authors

Yueyang Tong

Zhemin Feng

Yaqian Li

Chenxi Yan

Wenbo He

Xueyuan Chen

Affiliations

Soon will be listed here.

Abstract

Background: LncRNA TP73-AS1 has been revealed to exert a noteworthy impact on the occurrence and advancement of different cancers. In this study, we explored the function of TP73-AS1 in tumor growth, cell progression as well as the relevant molecular mechanism in non-small-cell lung cancer (NSCLC).

Methods: QRT-PCR was employed to assess the expression of TP73-AS1, miR-125a-3p, and actinin alpha 4 (ACTN4) in NSCLC cells. The biological effect of TP73-AS1 on NSCLC cells was assessed by cell transfection, CCK8, and transwell experiments. We further predicted the interaction among RNAs (TP73-AS1, miR-125a-3p, and ACTN4) through bioinformatics online tools and verified via luciferase reporter, RNA immunoprecipitation, and qRT-PCR assays. Xenograft models of SPC-A1 cells were conducted to test how TP73-AS1 regulates tumorigenesis. Western blot, as well as the immunohistochemistry (IHC) assays, was utilized to measure the expression levels. Functions of TP73-AS1 in NSCLC progression through the miR-125a-3p/ACTN4 axis were investigated by rescue experiments.

Results: Knockdown of TP73-AS1 suppressed the growth and simultaneously attenuated the migration and invasion ability of NSCLC SPC-A1 and A549 cells. Bioinformatics and molecular mechanism assays demonstrated that TP73-AS1 could bind to miR-125a-3p/ACTN4 and regulate their expression. Moreover, the rescued-function experiment demonstrated that suppressing miR-125a-3p or elevating ACTN4 turned around the suppression effect of sh-TP73-AS1 on NSCLC progression. TP73-AS1 inhibition could also inhibit the NSCLC tumor growth and correspondingly regulated the expression of miR-125a-3p and ACTN4 in the tumor xenograft model.

Conclusion: The present study indicated that TP73-AS1 affects NSCLC progression through a new competitive RNA (ceRNA) regulatory network of miR-125a-3p/ACTN4, providing an underlying target for NSCLC treatment in the future.

Citing Articles

Prognostic significance of LINC01132 in lung cancer and its regulatory role in tumor progression.

Hu Y, Wei Y Discov Oncol. 2024; 15(1):49.

PMID: 38403680 PMC: 10894788. DOI: 10.1007/s12672-024-00884-7.

Baicalin Relieves Airway Inflammation in COPD by Inhibiting miR-125a.

Jing X, Huo J, Li L, Wang T, Xu J Appl Biochem Biotechnol. 2023; 196(6):3374-3386.

PMID: 37656356 DOI: 10.1007/s12010-023-04671-y.

References

Wang M, Herbst R, Boshoff C . Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021; 27(8):1345-1356. DOI: 10.1038/s41591-021-01450-2. View

Koch L . Functional genomics: Screening for lncRNA function. Nat Rev Genet. 2017; 18(2):70. DOI: 10.1038/nrg.2016.168. View

Honda K, Yamada T, Hayashida Y, Idogawa M, Sato S, Hasegawa F . Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology. 2005; 128(1):51-62. DOI: 10.1053/j.gastro.2004.10.004. View

Shang R, Wang M, Dai B, Du J, Wang J, Liu Z . Long noncoding RNA SLC2A1-AS1 regulates aerobic glycolysis and progression in hepatocellular carcinoma via inhibiting the STAT3/FOXM1/GLUT1 pathway. Mol Oncol. 2020; 14(6):1381-1396. PMC: 7266282. DOI: 10.1002/1878-0261.12666. View

Thai A, Solomon B, Sequist L, Gainor J, Heist R . Lung cancer. Lancet. 2021; 398(10299):535-554. DOI: 10.1016/S0140-6736(21)00312-3. View

Zhu D, Zhou J, Liu Y, Du L, Zheng Z, Qian X . LncRNA TP73-AS1 is upregulated in non-small cell lung cancer and predicts poor survival. Gene. 2019; 710:98-102. DOI: 10.1016/j.gene.2019.05.044. View

Jung J, Kim S, An H, Ko J . α-Actinin-4 regulates cancer stem cell properties and chemoresistance in cervical cancer. Carcinogenesis. 2019; 41(7):940-949. DOI: 10.1093/carcin/bgz168. View

Hou L, Luo P, Ma Y, Jia C, Yu F, Lv Z . MicroRNA-125a-3p downregulation correlates with tumorigenesis and poor prognosis in patients with non-small cell lung cancer. Oncol Lett. 2017; 14(4):4441-4448. PMC: 5649526. DOI: 10.3892/ol.2017.6809. View

Wang M, Chang Y, Wu C, Tyan Y, Chang H, Goan Y . Alpha-actinin 4 is associated with cancer cell motility and is a potential biomarker in non-small cell lung cancer. J Thorac Oncol. 2014; 10(2):286-301. DOI: 10.1097/JTO.0000000000000396. View

10.

Jiang L, Chang J, Zhang Q, Sun L, Qiu X . MicroRNA hsa-miR-125a-3p activates p53 and induces apoptosis in lung cancer cells. Cancer Invest. 2013; 31(8):538-44. DOI: 10.3109/07357907.2013.820314. View

11.

Statello L, Guo C, Chen L, Huarte M . Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2020; 22(2):96-118. PMC: 7754182. DOI: 10.1038/s41580-020-00315-9. View

12.

Liu X, Chu K . α-Actinin-4 promotes metastasis in gastric cancer. Lab Invest. 2017; 97(9):1084-1094. DOI: 10.1038/labinvest.2017.28. View

13.

Filipowicz W, Jaskiewicz L, Kolb F, Pillai R . Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol. 2005; 15(3):331-41. DOI: 10.1016/j.sbi.2005.05.006. View

14.

Zhang H, Zhu X, Li N, Li D, Sha Z, Zheng X . miR-125a-3p targets MTA1 to suppress NSCLC cell proliferation, migration, and invasion. Acta Biochim Biophys Sin (Shanghai). 2015; 47(7):496-503. DOI: 10.1093/abbs/gmv039. View

15.

Wang J, Yan F, Zhao Q, Zhan F, Wang R, Wang L . Circulating exosomal miR-125a-3p as a novel biomarker for early-stage colon cancer. Sci Rep. 2017; 7(1):4150. PMC: 5482839. DOI: 10.1038/s41598-017-04386-1. View

16.

Zhang Y, Tabataba H, Liu X, Wang J, Yan X, Farrelly M . ACTN4 regulates the stability of RIPK1 in melanoma. Oncogene. 2018; 37(29):4033-4045. DOI: 10.1038/s41388-018-0260-x. View

17.

Yin H, Sun Y, Wang X, Park J, Zhang Y, Li M . Progress on the relationship between miR-125 family and tumorigenesis. Exp Cell Res. 2015; 339(2):252-60. DOI: 10.1016/j.yexcr.2015.09.015. View

18.

Dai S, Li N, Zhou M, Yuan Y, Yue D, Li T . LncRNA EBLN3P promotes the progression of osteosarcoma through modifying the miR-224-5p/Rab10 signaling axis. Sci Rep. 2021; 11(1):1992. PMC: 7820338. DOI: 10.1038/s41598-021-81641-6. View

19.

Li J, Meng H, Bai Y, Wang K . Regulation of lncRNA and Its Role in Cancer Metastasis. Oncol Res. 2016; 23(5):205-17. PMC: 7838649. DOI: 10.3727/096504016X14549667334007. View

20.

Jiang M, Ni J, Cui W, Wang B, Zhuo W . Emerging roles of lncRNA in cancer and therapeutic opportunities. Am J Cancer Res. 2019; 9(7):1354-1366. PMC: 6682721. View